ERBB2 and breast cancer: In breast cancer, for example, clear differences have been noted in markers like cytokeratin, HER2, E-cadherin and c-MYC within single tumors, highlighting the intra- and interpatient heterogeneity that can be captured with IMC (Giesen et al., 2014; Wagner et al., 2019).